Search PubMed⌕ Search

Biomedical subjects

R Launois

Publications and source records attributed to R Launois.

26 records · Page 2Linked to original sources
PubMed1989

[Economic evaluation of therapeutic strategies. Finality, methods].

The search for efficiency is the ultimate goal of economic evaluation. This article describes 3 principles for operational appraisal of medical strategies, lists the variables which have to be considered and reviews the main concepts of cost effectiveness, cost benefit and cost utility analysis.

Cost-Benefit Analysis↗
PubMed1989

[Cost efficacy analysis of thrombolytic strategies].

Price disparities of thrombolytic agents and variability in complementary reperfusion therapies have a big impact on hospital costs of thrombolysis. Nine strategies combining 3 thrombolytic preparations (SK alone, SK + aspirin and rt-PA) and 3 strategies for the management of reocclusion are compared. Unit costs of cardiac catheterisation and surgery and direct cost of a hospital day were estimated from hospital accounts. The hypotheses concerning the frequency of interventions and length of stay were based on results in the literature and analysis of a series of 420 patients from 3 hospital centres. The average direct cost of hospitalisation per patient treated with streptokinase plus aspirin with a conservative approach was 22,500 FF. It increased by 15 p. 100 with delayed elective angioplasty and by 45 p. 100 with an aggressive reperfusion strategy. In a conservative protocol, hospital costs were 37 p. 100 higher when rt-PA was used instead of streptokinase. An rt-PA conservative management strategy was associated with a twenty times higher cost per additional survivor than that of streptokinase with aspirin.

Cost-Benefit Analysis↗
PubMedDate not supplied

[Evaluation of the quality of life of schizophrenic patients: validation of the brief version of the Quality of Life Interview].

UNLABELLED: The main objective of the study was to determine the psychometric properties (mainly, validity and reliability) of the French language version of the brief Quality of Life Interview (QoLI). That instrument evaluates both the subjective and objective aspects of quality of life. METHODS: 128 patients fulfilling the DSM IV criteria for schizophrenia were included. Quality of life was evaluated using the brief QoLI. Schizophrenic symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS). The validity of the internal structure of the QoLI was investigated by means of item analysis, study of the correlations between the items and between the item-dimensions and principal component analysis addressing the subjective fields. The validity of the external structure was mainly investigated through the nomological validity study. The reliability of the scale was evaluated by studying the internal consistency. In addition, the acceptability of the scale was documented. RESULTS: The results of the study of the validity of the internal structure confirmed the pertinence of the pre-defined fields, particularly the subjective fields. Only some of the subjective fields of the QoLI showed significant correlations with the PANSS sub-scales. The acceptability of the scale was satisfactory. CONCLUSIONS: The psychometric properties of the French language version of the brief QoLI appeared satisfactory. The brief QoLi was shown to be an easily used instrument for assessment of the various objective and subjective aspects of the quality of life of schizophrenic patients.

Adult↗
PubMedDate not supplied

[Quality is expensive].

Over the past decade, as pressure to control costs has accelerated, the term cost effective has come increasingly into common usage. The central purpose of cost-effectiveness analysis is to compare the relative value of different interventions in creating better health. This article presents the rationale for using such an approach to prioritize public and private healthcare programmes.

Cost Control↗
PubMedDate not supplied

[Cost of illness: an inextricable maze or an aid in decision making? The case of schizophrenia].

The cost of schizophrenia has been a major point of interest abroad. In the United States, two authors evaluated the direct cost of the illness. According to Gunderson and Mosher (13), it reaches US $25,625 million. In the United Kingdom, the estimations are of 390 million pounds (7) and 1,178 million pounds (16). In Australia, a direct cost calculation based on incidence leads to US $24,621 million (1), which is 6 times as much as the cost of infarction. At last, the only French study (Rouillon et al., 1997) gives a result of FF 17,911 millions. The indirect cost estimations vary from 71% (29) to 83% (13) of the total cost. The difference between the 6 publications are suprizing (especially when they concern the same country) and are probably link to the difference of methodology. This point tempers largely the interest of these studies as a tool in order to hierarchise Public Health priorities. Moreover, the elaboration of structures equivalencies between the different countries is an ambitious enterprise and make difficult comparisons of the studies. Finally, the lack of transparency of some of them limits their credibility.

Cost Control↗